Citations

Clear

949 citation(s) found for "Li, Bryan".

Safety and efficacy of preoperative embolization in the treatment of brain arteriovenous malformations with perinidal aneurysms and single draining vein: a multicenter study with propensity score-weighting
Adeeb, Nimer , Abdalrazeq, Hammam , Salim, Hamza , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Ogilvy, Christopher S. , Sheehan, Jason , Aslan, Assala , Patel, Pious D. , Lan, Matthews , Baldassari, Michael P. , Koduri, Sravanthi , Atallah, Elias , Zeineddine, Hussein A. , Pontarelli, Mary-Katharine , Naamani, Kareem El, Ironside, Natasha , Gummadi, Sanjeev, Başkaya, Mustafa K. , Ataoglu, Cagdas , Mccarthy, Finn, Sanchez‐Forteza, Anthony , Essibayi, Muhammed Amir , Muram, Sandeep , Sconzo, Daniel , Riina, Howard A. , Rezai, Arwin, Alwakaa, Omar , Erginoğlu, Ufuk , Sen, Rajeev , Devia, Diego A., Perez-Mendez, Wilfran, Puentes, Juan C. , Spiotta, Alejandro M , Puri, Ajit S , Singh, Jasmeet, Burkhardt, Jan Karl, Starke, Robert M., Sekhar, Laligam N., Haranhalli, Neil , McAvoy, Malia , Eltiti, Marah, Abushehab, Abdallah, Foreman, Paul M. , Zaidat, Osama O. , Ruppert-Gomez, Marcella , Stapleton, Christopher J. , Koch, Matthew J. , Srinivasan, Visish M, Alshahrani, Rabab, Gooch, M Reid, Rosenwasser, Robert H. , Bulsara, Ketan R., Kan, Peter , Kim, Louis J. , Pukenas, Bryan , Li, Yan-Lin , Alaraj, Ali , Fuschi, Maurizio , Patel, Aman B. , Notarianni, Christina , Cuellar, Hugo H, Lawton, Michael T., Guthikonda, Bharat , Jabbour, Pascal , Salim, Hamza , Tjoumakaris, Stavropoula , Kandregula, Sandeep , Ogilvy, Christopher S , Dmytriw, Adam A , Aslan, Assala , Essibayi, Muhammed Amir , Alwakaa, Omar , Griessenauer, Christoph J , Abo Kasem, Rahim , Spiotta, Alejandro M , Levitt, Michael R , Altschul, David J , Shakir, Hakeem J , Zaidat, Osama O , Stapleton, Christopher , Koch, Matthew J , Chen, Peng R , Kan, Peter , Choudhri, Omar , Alaraj, Ali , Guthikonda, Bharat , Jabbour, Pascal , Erginoglu, Ufuk , Li, Yan-Lin , Burkhardt, Jan‐Karl , Musmar, Basel , Roy, Joanna M. , Kondziolka, Douglas , Dmytriw, Adam A. , Abou‐Al‐Shaar, Hussam , Naamani, Kareem El, Abdelsalam, Ahmed , Kumbhare, Deepak , Mccarthy, Finn, Keleş, Abdullah , Tos, Salem M , Mantziaris, Georgios , Park, Min S, Hanalıoğlu, Şahin , Pöppe, Johannes , Sen, Rajeev D, Griessenauer, Christoph J. , Ocampo-Navia, María Isabel , Kasem, Rahim Abo , Kühn, Anna Luisa , Sekhar, Laligam N. , Levitt, Michael R. , Altschul, David , Almajali, Mohammad , See, Alfred P. , Abla, Adib A. , Patel, Aashay , Nguyen, Andrew , Srinivasan, Visish M. , Blackburn, Spiros , Gooch, Michael Reid , Kim, Louis J. , Choudhri, Omar , Simonato, Davide , Savardekar, Amey Rajan , Lawton, Michael T. , Morcos, Jacques J.

Mayo Clinic

Journal of NeuroInterventional Surgery | August 22, 2025 | Volume: 18 | Issue: 8 | Pages: 1765-1772

10.1136/jnis-2025-023873 | PMID 40846482 Get It

Background and objectives Arteriovenous malformations (AVMs) with perinidal aneurysms and single draining vein are associated with an elevated risk of rupture and increased procedural complexity. The role of preoperative embolization in this high-risk anatomical subset remains unclear. This study aimed to evaluate the safety and efficacy of microsurgery with preoperative embolization, compared with microsurgery alone in patients with such AVMs. Methods We conducted a multicenter retrospective analysis of an AVM registry from the MISTA (Multicenter International Study for Treatment of Brain AVMs) consortium and included AVMs with perinidal aneurysms and a single draining vein. Baseline characteristics, angiographic outcomes, functional outcomes, and complication rates were compared. Propensity score weighting (PSW) using the covariate balancing method was applied to adjust for baseline differences. Results Out of a total of 1919 patients, 65 met the inclusion criteria; 45 patients underwent preoperative embolization followed by microsurgery, and 20 underwent microsurgery alone. After adjustment, complete obliteration rates were similar between groups (OR 0.87, 95% CI 0.04 to 16.33, P=0.92), as were rates of functional independence at discharge and follow-up. Overall complication, symptomatic complication, and mortality rates did not differ significantly between groups. However, permanent complications were significantly lower in patients with preoperative embolization (OR 0.06, 95% CI 0.004 to 0.84, P=0.03). Discussion In patients with AVMs featuring perinidal aneurysms and single draining vein, preoperative embolization followed by microsurgery was associated with fewer permanent complications and no increase in adverse outcomes compared with microsurgery alone. However, given the small number of events, this finding should be interpreted cautiously.
Cerebellum mitochondrial DNA copy number is increased in Parkinson’s disease
Beglarian, Talia , Tyrpak, David R. , MacKay, J. Andrew , Scholz, Sonja W. , Albert, Marilyn S. , Dawson, Ted M. , Troncoso, Juan C. , Hernandez, Dena G., Cookson, Mark R , Singleton, Andrew B., Beach, Thomas G., Hjelm, Brooke E. , MacKay, John Andrew , Scholz, Sonja W , Dawson, Ted M , Cookson, Mark , Adler, C H , Serrano, Geidy E , Hjelm, Brooke E , Gibbs, J. Raphael , Traynor, Bryan J , Rosenthal, Liana S. , Adler, Charles H. , Serrano, Geidy E. , Singleton, Andrew B., Beach, Thomas G.

Mayo Clinic

Brain Communications | August 20, 2025 | Volume: 7 | Issue: 4 | Pages: No page available

10.1093/braincomms/fcaf296 | PMID 40873892 Get It

Abstract Bioinformatics methods can be used to quantify mitochondrial DNA copy number from whole genome sequencing (WGS) data. We evaluated mitochondrial DNA copy number from human brain-derived WGS data using the fastMitoCalc tool. 341 Parkinson’s Disease cerebellum samples were compared with 74 age-matched controls from the North American Brain Expression Consortium. Parkinson’s Disease cerebellum had significantly higher mitochondrial DNA copy number compared with controls (P = 4.15e–7), and this effect was reproducible in four of five brain banks when analysis was restricted to each resource that contributed Parkinson’s Disease samples to this genetic dataset. Follow-on analyses of 128 Parkinson’s Disease cerebellum samples and 33 controls that had paired neuropathology data and clinical scores demonstrated a significant increase in mitochondrial DNA copy number with Unified Staging System for Lewy Body disorders stages and Unified Parkinson’s Disease Rating Scale (off meds) motor scores. Analysis of Lewy Body scores from ten brain regions showed cerebellum mitochondrial DNA copy number increased upon pathological infestation of α-synuclein aggregates in the brainstem and limbic system but did not increase after late-stage neocortical involvement. This genetics dataset supports previous observations of cerebellum activation in Parkinson’s Disease and suggests mitochondrial DNA copy number may increase to support this regional activation as a compensatory mechanism to pathology or motor symptoms.
The Timing of Direct Oral Anticoagulant Usage Did Not Impact Outcomes Following Hip Arthroplasty for Femoral Neck Fractures
Chen, Xiao T. , Springer, Bryan D. , Borkar, Shalmali R. , Spaulding, Aaron , Yang, Linjun , Wyles, Cody C. , Bingham, Joshua S. , Wilke, Benjamin K. , Borkar, Shalmali , Porter, Steven B , Wilke, B K , Spaulding, Aaron , Wyles, Cody C , Bingham, Joshua S , Yang, Linjun , Porter, Steven B.

Mayo Clinic

Journal of Bone and Joint Surgery | July 10, 2025 | Volume: 107 | Issue: 16 | Pages: 1857-1866

10.2106/jbjs.24.01293 | PMID 40638713 Get It

Background: Orthopaedic surgeons routinely delay surgical management of femoral neck fractures in patients taking direct oral anticoagulants (DOACs) to decrease perioperative bleeding and associated complications. However, this practice contradicts the principles of hip fracture management, as early surgery is associated with morbidity and mortality benefits. The purpose of this study was to quantify the association of DOAC use and perioperative outcomes in patients who underwent hemiarthroplasty (HA) or total hip arthroplasty (THA) for femoral neck fractures. We hypothesized that early surgical intervention on a patient taking a DOAC medication would not lead to worse perioperative outcomes. Methods: A retrospective cohort study was conducted on 2,833 patients who underwent primary THA or HA for femoral neck fractures between December 31, 2017, and January 29, 2024, across our hospital system. The patients taking a DOAC were divided into 3 groups based on the time since the last DOAC intake: 1 day, 2 days, and ≥3 days. Propensity matching was performed 1:1, accounting for age, sex, Elixhauser Comorbidity Index, preoperative chronic kidney disease stage, preoperative hemoglobin, body mass index, and hospital type. Subanalyses utilizing linear and conditional logistic regression models were performed to assess differences in outcomes between the groups that had a DOAC withheld and the control groups. Results: The mean age of all patients was 81 ± 10 years, 1,805 patients (64%) were women, and 207 patients (7%) were taking a DOAC prior to surgery. Despite comparable preoperative and postoperative hemoglobin levels between the groups that had a DOAC withheld and the control groups (all p > 0.05), the patients who had a DOAC withheld for 1 day were more likely to receive a postoperative blood transfusion (23.1% compared with 0%; p = 0.002). This difference in transfusion rate was not observed in other cohorts. There were no differences in medical complications, reoperation, discharge disposition, or mortality between the groups that had a DOAC withheld and the matched controls at any time point. Conclusions: Delaying surgical management due to DOAC medications may be unnecessary in patients undergoing arthroplasty for femoral neck fractures. Consideration should be given to adjusting transfusion triggers to reduce unwarranted blood transfusions in patients taking a DOAC. Level of Evidence: Therapeutic Level III . See Instructions for Authors for a complete description of levels of evidence.
Discrepancies between CSF biomarker and PET determinations of elevated brain amyloid and their prognostic significance
Weigand, Stephen D. , Wiste, Heather J. , Graff‐Radford, Jonathan, Graff‐Radford, Neill R., Petersen, Ronald C., Jack, Clifford R. , Lowe, Val J. , Fields, Julie A. , Neth, Bryan J. , Day, Gregory S. , Kantarci, Kejal, Bornhorst, Joshua A. , Initiative, and the Alzheimer's Disease Neuroimaging, Kantarci, Kejal , Neth, Byran J. , Jack, Clifford R , Kantarci, Kejal , Day, Gregory S , Bornhorst, Joshua , Knopman, David S. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Petersen, Ronald C. , Boeve, Bradley F. , Machulda, Mary M. , Ramanan, Vijay K. , Botha, Hugo , McCarter, Stuart J. , Jones, David T. , Algeciras‐Schimnich, Alicia , Johnson, Derek R. , Initiative, and the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | July 9, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70468 | PMID 40631430 Get It

Abstract INTRODUCTION When cerebrospinal fluid (CSF) and positron emission tomography (PET) measurements for amyloid‐beta‐peptide (Aβ) related pathology are discordant, therapeutic decision‐making becomes uncertain. METHODS Using data from patients with mild cognitive impairment ( n = 541) from the Alzheimer's Disease Neuroimaging Initiative, we examined baseline characteristics and longitudinal clinical outcomes in persons grouped according to normal/abnormal Aβ via concurrent CSF and PET determinations using standard cutpoints. RESULTS Discordant groups for brain Aβ status (CSF+/PET− and CSF−/PET+) each represented about 5% of the mild cognitive impairment (MCI) population. Longitudinally, neither discordant group declined more than the CSF−/PET− group on either a memory measure or the Clinical Dementia Rating Sum of Boxes scores over a median 4 years of observation, while the CSF+/PET+ group exhibited worsening on both measures. DISCUSSION In contrast to the clinical decline observed in the CSF+/PET+ group, persons with MCI and CSF+/PET− or CSF−/PET+ brain amyloid patterns did not exhibit incipient decline. Highlights Discrepant abnormal cerebrospinal fluid (CSF) and positron emission tomography (PET) brain amyloid indicators are uncommon in mild cognitive impairment (MCI). CSF‐PET discrepant persons with MCI tend to have less abnormal values initially. CSF‐PET discrepant persons with MCI have a benign prognosis at 4 years.
Epidemiology of Elbow Medial Ulnar Collateral Ligament Surgeries in Major and Minor League Baseball Pitchers: A Descriptive Study of 2281 Cases
Meta, Fabien , Meister, Keith, Griffith, Timothy B. , Conte, Stan, Chalmers, Peter N., Mavrommatis, Sophia , Hebert, Elizabeth, Clark, Sean C. , Griffith, Timothy Bryan , Chalmers, Peter N. , Hebert, Elizabeth, Camp, Christopher L.

Mayo Clinic

Orthopaedic Journal of Sports Medicine | July 7, 2025 | Volume: 13 | Issue: 7 | Pages: No page available

10.1177/23259671251352199 | PMID 40630505 Get It

Background: Injuries of the medial ulnar collateral ligament (MUCL) among baseball pitchers are increasing. Surgical treatment is evolving to optimize outcomes. Purpose/Hypothesis: This study’s purpose was to highlight trends in MUCL repair and reconstruction in professional pitchers, describe outcomes such as return to any level of play (RTP), and identify factors impacting these outcomes. It was hypothesized that primary and revision MUCL surgery is increasing, with revision surgery requiring greater RTP time. Study Design: Case series; Level of evidence, 4. Methods: The Major League Baseball (MLB) Health and Injury Tracking System database was used to procure data during the study period (2010-2023). All professional pitchers who underwent MUCL surgery during this period were included. RTP was defined as a pitcher returning to at least 1 professional game after index surgery. Return to the same level of play (RTSL) was defined as return to at least 1 game in the same league of play as before surgery. Because of the coronavirus pandemic, the year 2020 was considered an outlier and omitted from time-trend analysis. Results: A total of 2281 pitchers who underwent MUCL surgery during the study period were included for analysis. The number of MUCL surgeries for pitchers increased yearly ( R 2 = 0.821; P < .001), as did the number of reconstructions with internal brace augmentation ( R 2 = 0.896; P < .001). The RTP rate for MLB pitchers was significantly higher than the RTSL rate (93% vs 71%; P < .001). This difference was not observed in Minor League Baseball (MiLB) pitchers (RTP 76% vs RTSL 74%; P = .142). RTP rates after revision surgery were lower than those after primary surgery (71% vs 80%; P = .020). The mean time to RTP was shorter (470 ± 135 days) than the mean time to RTSL (499 ± 153 days; P < .001). Conclusion: The incidence of MUCL surgery and revision surgery is increasing among professional pitchers. Overall, 79% of pitchers returned to any level of play at a mean of 470 days, while 74% returned to the same level of play at a mean of 499 days, but this varied based on level of play. This study will guide athlete expectations and surgeon decision-making.
Advancements in Visual Field Testing: A Systematic Review of the 24-2C Test Grid
Jin, Eric , Wong, Natalie Shi Qi , Goh, Claire Xin Yi, Stewart, Michael W., Dorairaj, Syril, Ang, Bryan Chin Hou , Ang, Bryan C H , Dorairaj, Syril

Mayo Clinic

Bioengineering | July 1, 2025 | Volume: 12 | Issue: 7 | Pages: 711

10.3390/bioengineering12070711 | PMID 40722403 Get It

A systematic review was conducted of studies published up to 30 August 2024. Studies comparing conventional visual field (VF) indices, ability to detect central visual field defects (CVFDs), structure–function (S-F) concordance, and test characteristics across the HVF 24-2C SITA-Faster, 24-2 SITA-Standard/Faster, and 10-2 SITA-Standard/Fast tests were included. Eight studies with 1239 subjects (49.1% male; mean age, 54.8–66.9 years) were analyzed. The 24-2C produced similar global VF indices compared to the 10-2 and 24-2 (Standard/Faster) (ICC = 0.95 and 0.80, p < 0.001), detected more VF defects and CVFD clusters, and demonstrated greater S-F concordance than the 24-2 (Standard/Faster). Although the 10-2 (Standard/Fast) detected significantly more CVFDs and had a greater S-F concordance, the agreement between the 24-2C and 10-2 grids was substantial (ĸ = 0.488 to 0.708). The 24-2C was also faster compared to the 24-2 Standard and 10-2 (Standard/Fast), with comparable false positives, higher false negatives, and fewer fixation losses than the 24-2 Standard. In conclusion, the HVF 24-2C is quicker and identifies more CVFDs than the 24-2 grid, demonstrates high agreement with the 10-2 grid, and aids in CVFD screening.
Successful Treatment of Recurrent Airway Stenosis With Paclitaxel‐Coated Balloons: A Case Report
Gutierrez‐Gallegos, Paola , Vu, Linh H. , Lee‐Mateus, Alejandra Yu , Malla, Milan , Valdes‐Camacho, Sofia , Vaca‐Cartagena, Bryan F. , Valencia‐Sanchez, Bastien A., Anderson, Elise , Fernández-Bussy, Sebastián , Yu Lee-Mateus, Alejandra , Barrios-Ruiz, Alanna, Fernandez-Bussy, Sebastian , Barrios‐Ruiz, Alanna , Valencia‐Sanchez, Bastien A., Abia‐Trujillo, David , Malla, Milan

Mayo Clinic

Respirology Case Reports | June 26, 2025 | Volume: 13 | Issue: 6 | Pages: No page available

10.1002/rcr2.70261 | PMID 40575399 Get It

ABSTRACTAlthough current treatment strategies for nonmalignant airway stenosis may offer short‐term relief, their effectiveness is limited by high recurrence rates, often requiring additional procedures. While paclitaxel‐coated balloons (PCB) have demonstrated effectiveness in treating stenosis across various vascular and nonvascular conditions, their evidence in recurrent airway stenosis remains limited. Here, we present the case of a 35‐year‐old female with bronchial stenosis who underwent multiple bronchoscopic interventions, all of which were complicated by restenosis. Following the addition of a PCB to the therapeutic regimen, the patient achieved sustained airway patency.
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus–Initiated Oropharynx Cancer
Flamand, Yael , Quon, Harry , Weinstein, Gregory S., Mehra, Ranee , Garcia, Joaquin J., Kim, Seungwon , O’Malley, Bert W. , Özer, Enver , Ikpeazu, Chukwuemeka , Koch, Wayne M. , Lango, Miriam N. , Smith, Russell K., Karakla, Daniel W., Richmon, Jeremy D. , Burtness, Barbara , Flamand, Yael , Quon, Harry , Mehra, Ranee , Ikpeazu, Chukwuemeka , Gross, Neil D , Bell, R Bryan , Lango, Miriam , Morris, Luc G T , Holsinger, F Chris , Ferris, Robert L , Richmon, Jeremy D , Burtness, Barbara , Garcia, Joaquin J., Bell, R. Bryan , Patel, Mihir R , Holsinger, F. Christopher , Ferris, Robert L.

Mayo Clinic

Journal of Clinical Oncology | June 10, 2025 | Volume: 43 | Issue: 23 | Pages: 2559-2565

10.1200/jco-24-02550 | PMID 40493877 Get It

This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human papillomavirus (HPV)–associated oropharynx cancer (OPC) enrolled patients with resectable cT1-2 stage III/IV American Joint Committee on Cancer (AJCC) seventh edition p16+ OPC without matted neck nodes. Those with clear margins, 0-1 + nodes (LN), and no extranodal extension (ENE) were observed (arm A); those with clear margins, 2-4 + LN, or ENE ≤1 mm were randomly assigned to 50 Gy (arm B) or 60 Gy (arm C); and those with involved margins, >4 + LN, or >1 mm ENE received weekly cisplatin and 60-66 Gy (arm D). Among 359 evaluable patients, the 54-month progression-free (PFS) and overall survival (OS) were 90.6% (90% CI, 87.2% to 93.1%) and 95.3% (93.0% to 96.9%), respectively. The 54-month PFS by arm was A 93.2% (79.6% to 97.8%; all four recurrences among N1 patients), B 94.9% (89.7% to 97.5%), C 90.2% (82.7% to 94.6%), and D 85.5% (77.5% to 90.8%). The 54-month OS by arm was A 97.1% (85.7% to 99.4%), B 97.9% (93.5% to 99.3%), C 95.1% (90.1% to 97.6%), and D 92.5% (86.9% to 95.7%). PFS or OS did not differ by primary site or smoking history. TOS and neck dissection with deintensified postoperative management results in outstanding 54-month PFS and OS. Among patients with favorable pathologic characteristics, those with N1 disease are at risk of late recurrence without radiation.
AAPM task group report 351: Protocol for clinical reference dosimetry in external beam MR‐guided radiotherapy
Sarfehnia, Arman , Alvarez, P , Bellon, M, Bouchard, Hugo , Dolan, James E., Malkov, Victor , Asselen, Bram van , Wolthaus, J., Prez, Leon de , Dolan, James E., Ibbott, Geoffrey S. , Muir, Bryan , Rogers, D. W. O. , Yadav, Poonam

Mayo Clinic

Medical Physics | May 29, 2025 | Volume: 52 | Issue: 7 | Pages: No page available

10.1002/mp.17884 Get It

Abstract Background Magnetic Resonance‐guided Radiation Therapy (MRgRT) systems are increasingly used in clinical practice, necessitating a dedicated dosimetry protocol to address the challenges posed by the presence of strong magnetic fields. Purpose AAPM TG351 introduces a reference dosimetry protocol for external beam MRgRT systems, aligning with AAPM TG51 reports and incorporating elements from the IAEA TRS398 code of practice. Methods The protocol offers practical guidance on beam quality and dosimetry setup in the presence of strong magnetic fields. It reviews relevant literature to identify reference‐class chambers suitable for external beam MRgRT systems and determines their beam quality conversion and other relevant correction factors through a detailed analysis of available data and associated uncertainties. Results AAPM TG351 offers a comprehensive dosimetry protocol for external beam MRgRT systems, addressing the unique challenges posed by the presence of magnetic fields. It includes detailed guidance for measurement setups, a list of reference‐class chambers appropriate for reference dosimetry in MRgRT systems, and updated beam quality conversion and correction factors. Additionally, the protocol presents an in‐depth analysis of the uncertainty budget, identifying key contributors and providing strategies to minimize uncertainties, thereby enhancing clinical accuracy and reliability. Conclusions This protocol provides a practical, evidence‐based reference for medical physicists conducting reference dosimetry in external beam MRgRT systems.